Specific human leukocyte antigen (HLA) alleles are associated with the formation of anti-drug antibodies to adalimumab in patients with rheumatoid arthritis and hidradenitis suppurativa, potentially causing reduced therapeutic response.
Specific human leukocyte antigen (HLA) alleles are associated with the formation of anti-drug antibodies to adalimumab in patients with rheumatoid arthritis (RA) and hidradenitis suppurativa (HS), potentially causing reduced therapeutic response, according to recent research by Mohan Liu, PhD, and colleagues published online in PLoS One.
Although certain HLA alleles are known to be associated with antibody formation against infliximab, the role of patient-related factors in determining anti-adalimumab antibody formation had not previously been shown. The results suggest that specific HLA alleles may play a key role in developing these antibodies in patients with RA and HS treated with adalimumab, the authors conclude.
The study received funding from AbbVie, maker of reference adalimumab (Humira). Two biosimilar adalimumab products have been approved by the FDA.
The researchers drew their study subjects from participants in 4 different phase 3 clinical trials that enrolled patients with RA or HS at sites predominantly in the United States and Europe. Patients with RA received subcutaneous injections of 40 mg of adalimumab every other week for up to 24 weeks, as well as weekly oral doses of methotrexate; patients with HS received 40 mg subcutaneous adalimumab injections every week or every other week for up to 36 weeks.
Samples from 634 subjects with either RA or HS were analyzed. Of this group, 37 subjects (17 with RA, 20 with HS) developed antibodies to adalimumab during treatment, and 597 subjects (348 with RA, 249 with HS) did not develop these antibodies during the clinical trials.
Using next-generation sequencing-based HLA typing, the researchers identified 3 specific protective HLA alleles that were less prevalent in antibody-positive subjects than in antibody-negative subjects (odds ratios [OR]: 0.4, 0.25, and 0.28, respectively) and 2 risk HLA alleles that were more abundant in antibody-positive than in antibody-negative subjects (OR: 2.52 and 2.64, respectively).
The 3 protective alleles were:
The 2 risk alleles were:
The researchers report that HLA-DRB1*03 is independently predictive of antibody formation in patients with RA and HS with adalimumab treatment and in patients with inflammatory bowel disease receiving infliximab treatment. “These results provide additional insight into underlying reasons for variable immunogenicity response across different patients treated with [anti—tumor necrosis factor] therapy,” they conclude.
Reference
Liu M, Degner J, Davis JW, Idler KB, Mostafa N, Waring JF. Identification of HLA-CRB1 association to adalimumab immunogenicity. PLoS One. 2018;13(4):e0195325. doi: 10.1371/journal.pone.0195325.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.